A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19
Wang-Da Liu(National Taiwan University Hospital), Wang‐Huei Sheng(National Taiwan University), Yu-Tien Tzeng(Wan Fang Hospital), Mei-Hui Lee(Taipei Medical University-Shuang Ho Hospital), Weichung Joe Shih(Rutgers, The State University of New Jersey), Mei-Chuan Chen(Taipei Medical University Hospital), Po‐Hao Feng(Taipei Medical University-Shuang Ho Hospital), Shang-Fu Hsu(Taipei Medical University Hospital), Chun‐Hsing Liao(Far Eastern Memorial Hospital), Chien‐Yu Cheng(Tao Yuan General Hospital), Cheng‐Pin Chen(Tao Yuan General Hospital), Tsong‐Yih Ou(Taipei Medical University Hospital), Po‐Yu Liu(National Chung Hsing University), Kang‐Yun Lee(Taipei Medical University-Shuang Ho Hospital), Min‐Chi Lu(China Medical University), Yi-Chun Lin(Tao Yuan General Hospital), Chih‐Hsin Lee(Wan Fang Hospital), Albert Qin, Chun-Liang Chou(Taipei Medical University Hospital), Chan‐Yen Tsai
Cited by 0
Related Papers
Prolonged virus shedding even after seroconversion in a patient with COVID-19
|Journal of Infection|2020|301
NF-κB and Activator Protein 1 Response Elements and the Role of Histone Modifications in IL-1β-Induced TGF-β1 Gene Transcription
|The Journal of Immunology|2006|167
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants
|DOAJ (DOAJ: Directory of Open Access Journals)|2022|76
MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-γ-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells
|Cancers|2019|40
Global mortality of chronic liver diseases attributable to Hepatitis B virus and Hepatitis C virus infections from 1990 to 2019 and projections to 2030.
|Journal of Infection and Public Health|2024|37